

ASX RELEASE 24 August 2023

Results of Annual General Meeting

Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to confirm that each of the resolutions put to its Annual General Meeting held earlier today were carried.

Details of the results of the meeting are attached.

This ASX announcement is authorised for release by the Company Secretary.

- End -

Investor Contact:

Dr Chris Burns Chief Executive Officer chris@ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx) and LinkedIn.

AMPLIA THERAPEUTICS LIMITED

Annual General Meeting Thursday, 24 August 2023

Results of Meeting



The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Remuneration Report	Ordinary	74,975,874	143,326	2,022,965	31,901	77,075,453	143,326	31,901	Carried
		97.19%	0.19%	2.62%		99.81%	0.19%		
2 Re-elect Dr Warwick Tong as a Director of the Company	Ordinary	81,442,615	55,500	2,022,965	3,100,247	83,542,194	55,500	3,100,247	Carried
		97.51%	0.07%	2.42%		99.93%	0.07%		
3 Approval for extra 10% Placement Facility	Special	70,601,912	13,964,568	2,022,965	31,882	72,701,491	13,964,568	31,882	Carried
		81.53%	16.13%	2.34%		83.89%	16.11%		
4 Proposed Issue of Options to Dr Christopher Burns (Managing Director and Chief Executive Officer)	Ordinary	74,885,377	181,724	2,022,965	5,628,045	76,984,956	181,724	5,628,045	Carried
		97.14%	0.24%	2.62%		99.76%	0.24%		

^{*} Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.